Showing 6541-6550 of 10001 results for "".
- Nanoparticulate-based Sunscreens May Not Be So Dangerous After Allhttps://practicaldermatology.com/news/nanoparticulate-based-sunscreens-may-not-be-so-dangerous-after-all/2457499/Zinc oxide nanoparticles used in sunscreen neither penetrate the skin nor cause cellular toxicity after repeated applications, according to a study out of University of Queensland (UQ) and University of South Australia, The
- Study: Novel 1060nm Diode Laser Is Safe and Effective for Hair Removalhttps://practicaldermatology.com/news/study-novel-1060-diode-laser-is-safe-and-effective-for-hair-removal/2457510/A novel 1060 nm diode laser system is safe and effective for hair removal and long-term hair reduction in all skin types including darkly pigmented individuals, according to research in Lasers in Surgery and Medicine (LSM)
- Cutanea Life Sciences Launches Xepi Creamhttps://practicaldermatology.com/news/cutanea-life-sciences-launches-xepi-cream-1/2457512/Cutanea Life Sciences, Inc. has launched Xepi™ (ozenoxacin) Cream, 1% for the treatment of impetigo in adult and pediatric patients two months of age or older. Xepi is a non-fluorinated topical quinolone indicated for the treatment of impetigo due to Staphylococcus aureus
- Study: Fine Water Particle Sprays Improve Facial Skin Moisture for Hourshttps://practicaldermatology.com/news/study-fine-water-particle-sprays-improve-facial-skin-moisture-for-hours/2457515/Spraying fine water particles onto the face in winter, when skin is dry, improved skin hydration and softening, according to a new study in Skin Research & Technology. In addition, water retention remained co
- US FDA Grants Dupixent Priority Review for Moderate-to-Severe AD in Adolescentshttps://practicaldermatology.com/news/us-fda-grants-dupixent-priority-review-for-moderate-to-severe-ad-in-adolescents/2457517/The US Food and Drug Administration (FDA) has granted Priority Review for Dupixent (dupilumab) as a potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis (AD). Currently, there are no FDA-approved systemic biologic medicines to treat adolescents with m
- Cooling Caps and Other Cooling Methods May Prevent Taxane-Induced Dermatologic Eventshttps://practicaldermatology.com/news/cooling-caps-and-other-cooling-methods-may-prevent-taxane-induced-dermatologic-events/2457523/Cooling therapies such as cold caps, scalp cooling systems, frozen gloves, and frozen socks may offer the best protection against the adverse effects of taxane-based chemotherapy, according to a new study in JAMA Dermatology. “Taxanes induce dermatologic changes through dir
- Opdivo Plus Yervoy Demonstrates Durable Four-Year Survival Benefits in Advanced Melanomahttps://practicaldermatology.com/news/opdivo-plus-yervoy-demonstrates-durable-four-year-survival-benefits-in-advanced-melanoma/2457552/Four-year data from the Phase 3 CheckMate-067 clinical trial—the longest follow-up to date—continue to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in
- Residents of Distinction Attend 2018 Coastal Dermatology Symposiumhttps://practicaldermatology.com/news/residents-of-distinction-attend-2018-coastal-dermatology-symposium/2457554/As part of the dermMentors Resident of Distinction Award program, sponsored by Beiersdorf Inc., five dermatology residents attended the 14th Annual Coastal Dermatology Symposium, held in Monterey, CA October 3-6, 2018. The 2018 dermMentors™
- Psoriasis Plus Hypertension Equals Greater Need for Heart Surgeryhttps://practicaldermatology.com/news/psoriasis-plus-hypertension-equals-greater-need-for-cardiovascular-interventions/2457559/Patients with psoriasis and hypertension need more cardiovascular procedures and surgeries than hypertensive patients without psoriasis, a new study in the Journal of Dermatology suggests. In 5.62 year
- New from Lumenis: NuEra Tight Radio Frequency Devicehttps://practicaldermatology.com/news/new-from-lumenis-nuera-tight-radio-frequency-device/2457558/Lumenis has launched NuEra tight, a non-invasive, intelligent temperature-controlled technology for both superficial and deep heating that treats a variety of conditions, such as skin laxi